Drug Profile
Smallpox therapeutic - BioFactura
Latest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator BioFactura
- Developer BioFactura; United States Army Medical Research Institute of Infectious Diseases
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Smallpox
Most Recent Events
- 13 Sep 2023 Preclinical development for Smallpox is ongoing in the US (BioFactura pipeline, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Smallpox in USA
- 27 Sep 2019 BioFactura enters in to an agreement with Biomedical Advanced Research and Development Authority (BARDA) for the development of its Smallpox Biodefense Therapeutic